

Mediclinic International plc
Incorporated in England and Wales
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
(‘Mediclinic’, or the ‘Company’, or the ‘Group’)

MEDICLINIC HALF-YEAR RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2022

GROUP FINANCIAL RESULTS

- Group revenue increased by 10% compared with 1H22 (up 2% in constant currency)
- Group adjusted EBITDA decreased by 1% compared with 1H22 (down 8% in constant currency), with an adjusted EBITDA margin of 14.2% (1H22: 15.8%), reflecting revenue impact and increased operating expenses
- Adjusted operating profit of £131m decreased by 11% compared with 1H22 (down 20% in constant currency)
- Operating profit down 8% to £119m (1H22: £129m)
- Adjusted earnings and adjusted earnings per share decreased by 15% compared with 1H22
- Reported earnings up 28% to £83m (1H22: £65m) and reported earnings per share up 28% to 11.3 pence (1H22: 8.8 pence)
- Headline earnings per share 11.3 pence (1H22: 8.8 pence)
- Operating performance and cash conversion of 72% (1H22: 104%) delivered cash and cash equivalents to £445m (FY22: £534m)
- Leverage ratio (including lease liabilities) at 4.4x (FY22: 3.9x), reflecting foreign exchange translation differences and lower cash conversion
- No interim dividend proposed in light of current offer for Mediclinic by Manta Bidco Limited (‘Bidco’) (a newly formed company owned by joint offerors: [i] Remgro Limited [‘Remgro’] [through certain subsidiaries]; and [ii] SAS Shipping Agencies Services S.à r.l. [‘SAS’], a wholly owned subsidiary of MSC Mediterranean Shipping Company SA)

FURTHER INFORMATION

The contents of this short-form announcement is the responsibility of the Board of Directors of the Company. This announcement represents a summary of the information contained in the unabridged results announcement. Any investment decisions by investors and/or shareholders should be based on a consideration of the unabridged announcement. The unabridged announcement can be accessed on the following JSE link:

<https://senspdf.jse.co.za/documents/2022/JSE/ISSE/MEIE/MEIHY23.pdf>

The announcement is also published on www.mediclinic.com and available for inspection at the registered office of the Company and the offices of the Company’s sponsor at no charge, during normal business hours.

CORPORATE INFORMATION

LISTINGS

The Company’s primary listing is on the London Stock Exchange in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

DIRECTORS

Inga Beale DBE (*ind ne*) (*Chair*) (*British*), Dr Ronnie van der Merwe (*Group Chief Executive Officer*) (*South African*), Jurgens Myburgh (*Group Chief Financial Officer*) (*South African*), Dr Felicity Harvey CBE (*Senior Independent Director*) (*British*), Dr Muhadditha Al Hashimi (*ind ne*) (*Emirati*), Natalia Barsegiyan (*ind ne*) (*French and Russian*), Zarina Bassa (*ind ne*) (*South African*), Jannie Durand (*ne*) (*South African*), Danie Meintjes (*ne*) (*South African*), Dr Anja Oswald (*ind ne*) (*Swiss*), Tom Singer (*ind ne*) (*British*), Steve Weiner (*ind ne*) (*American*), Pieter Uys (*alternate to Jannie Durand*) (*South African*)

COMPANY SECRETARY

Link Company Matters Limited (previously named Capita Company Secretarial Services Limited)

REGISTERED OFFICE

Mediclinic International plc
6th Floor, 65 Gresham Street
London, EC2V 7NQ, United Kingdom
Tel: +44 333 300 1930
Email: info@mediclinic.com
Website: www.mediclinic.com

TOLL-FREE ETHICS LINES AND EMAIL**Switzerland**

Tel: 0800 005 316

South Africa

Tel: 0800 005 316

Namibia

Tel: 0800 003 313

MTC Networks: 081 91847

The United Arab Emirates

Tel: 800 1 55000

Email: mediclinic@tip-offs.com

REGISTRAR/TRANSFER SECRETARIES**UK**

United Kingdom Computershare Investor Services PLC

SOUTH AFRICA

Computershare Investor Services (Pty) Ltd

NAMIBIA

Transfer Secretaries (Pty) Ltd

CORPORATE ADVISORS**AUDITOR**

PricewaterhouseCoopers LLP, London

CORPORATE BROKER AND SPONSORS**UK**

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

South Africa

JSE sponsor: Rand Merchant Bank (a division of FirstRand Bank Limited)

Namibia

NSX sponsor: Simonis Storm Securities (Pty) Ltd

APPROVED BY THE BOARD: 15 November 2022

SENS RELEASE DATE: 16 November 2022